Ticker

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). "This first commercial living donor transplant patient in Australia…

Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday,…

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase LUND, Sweden, July 1, 2026 /PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ Stockholm: HNSA) and…

Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript